Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Axsome Therapeutics ( (AXSM) ).
On August 19, 2025, Axsome Therapeutics received a Paragraph IV Certification Notice from Apotex, indicating that Apotex has filed an ANDA with the FDA to produce a generic version of Axsome’s Symbravo®. Axsome plans to respond to this notice, which could impact its market position and stakeholder interests.
The most recent analyst rating on (AXSM) stock is a Buy with a $189.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.
Spark’s Take on AXSM Stock
According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.
Axsome Therapeutics shows strong revenue growth and positive technical indicators, but profitability challenges and a negative valuation score weigh heavily. The earnings call provided a positive outlook, yet highlighted significant losses and market access issues.
To see Spark’s full report on AXSM stock, click here.
More about Axsome Therapeutics
Axsome Therapeutics operates in the pharmaceutical industry, focusing on developing therapies for central nervous system disorders.
Average Trading Volume: 629,216
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.55B
Learn more about AXSM stock on TipRanks’ Stock Analysis page.